VLON News and Press, Vallon Pharmaceuticals Inc. From 04/22/22

Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in t...

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel , today , March 2 3 rd at 9 : 0 0 AM ET Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (N...

Gainers: NeuroSense (NRSN) +333%. BitNile (NILE) +69%. Yumanity Therapeutics (YMTX) +50%. BT Brands (BTBD) +41%. Mullen Automotive (MULN) +39%. Hudson Capital (HUSN) +38%. O2Micro International (OIIM) +32%. Cenntro Electric Group (CENN) +33%. Akanda (AKAN) +29%. Anaplan (PLAN) +28%. Losers: V...

Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...

Clinical-stage biopharmaceutical company, Vallon Pharmaceuticals (NASDAQ:VLON) has lost ~77% in the pre-market Monday after announcing that its lead program for ADAIR did not meet primary endpoint in attention deficit hyperactivity disorder (ADHD). The pivotal SEAL study was designed to ...

– Study did not meet primary endpoint of significant reduction in E max Drug Liking for ADAIR vs reference d extroamphetamine , although a trend in favor of ADAIR was observed (p=0.1 6 ) – All pharmacodyna...

Global b iopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small biotech companies Philadelphia, PA, Feb. 28, 2022 (GLOBE...

- Company in ongoing disc ussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with COVID-19 PHILADELPHIA, PA, Feb. 28, 2...

Gainers: HOOKIPA Pharma HOOK +26%. Maris-Tech (NASDAQ:MTEK) +18%. Karyopharm Therapeutics KPTI +18%. Creative Medical Technology Holdings CELZ +15%. Cambium Networks (NASDAQ:CMBM) +16%. Inotiv NOTV +14%. Cyngn (NASDAQ:CYN) +14%. Vallon Pharmaceuticals (NASDAQ:VLON) +14%. A...

- T opline data for p ivotal abuse study of the C ompany’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with first-in-human ...